Lopinavir and Ritonavir Tablets

DRUG2 trials

Sponsors

Guangzhou 8th People's Hospital, DualityBio Inc.

Conditions

Advanced Solid TumorsCoronavirus Infections

Phase 1

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

RecruitingNCT05914116

DualityBio Inc.Advanced Solid Tumors

Start: 2023-08-17End: 2028-05-31Target: 862Updated: 2025-11-21

Phase 4

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

CompletedNCT04252885

Guangzhou 8th People's HospitalCoronavirus Infections

Start: 2020-01-28End: 2020-05-31Updated: 2020-07-01

Related Papers

BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2026-05-28

DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).

Journal of Clinical Oncology2025-05-282 citations

Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors

Cancer Research2024-04-051 citations

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.

2020-05-19213 citations